GE Healthcare has launched a second phase III (AURORA) clinical trial for using Flurpiridaz 18F Injection in positron-emission tomography (PET) myocardial perfusion imaging (MPI), in order to detect coronary artery disease (CAD).
Findings from two international, randomized, double-blind, phase III, placebo-controlled trials published in the September issue of Gastroenterology revealed that the oral second-generation thrombopoietin agonist avatrombopag (Doptelet) when given once a day, notably decreased the requirement for platelet transfusion...
A phase 2 study on BAN2401, a monoclonal antibody that hits soluble amyloid beta oligomers, showed that it limits cognitive decline in patients with slight cognitive injury or premature Alzheimer’s dementia on two scales and removed brain amyloid in 81% of patients in the trial.
Age-related Macular Degeneration (AMD) is the leading cause of blindness among the elderly. The most commonly used drugs to slow the progression of the disease is Roche’s Lucentis and Regeneron’s Eylea. These drugs are injected into the eye which, needless to say, leads to more inconvenience.
SMART Brain Aging, Inc. announced its one-on-one patient intervention program for aging brain health, Brain U Online, now available to adults above age 50 via online subscription and iOS app, Brain U Lite. Five years of clinical trials were carried out with more than 3,000 participants at Harvard Medical School/Boston University School of Medicine to develop this new program
The San Diego-based biotech company Crinetics Therapeutics recently raised $86 million in an IPO. Prior to the new funding, the company received $63.5 million in series B funding and will see its lead asset through phase 2.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.